Update on Lupuzor™ Pivotal Phase III Study – Patient Recruitment Completed

22nd December 2016 - 12:41 pm

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to confirm that patient recruitment has successfully been completed, on target, within the Company’s pivotal Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto-immune disease.

Commenting on this announcement, Tim McCarthy, Chairman of ImmuPharma said: “This is a major milestone for ImmuPharma confirming the completion of patient recruitment into this study. We look forward to providing further updates as and when possible on this pivotal Phase III trial as it progresses through 2017.”

Share this article